OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00256255

Brother Enterprises Holding Co Ltd

PharmaceuticalsVerified

Brother Enterprises Holding Co Ltd has a debt-to-equity ratio of 0.43, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a negative net cash position after subtracting total debt, suggesting potential short-term liquidity constraints. Operating cash flow for the latest period was 7,098,720 CNY, which is significantly lower in magnitude compared to capital expenditures of -73,804,460 CNY, indicating a net cash outflow from operations. In terms of profitability, the company's financial performance is not yet benchmarked against industry-specific metrics, as the industry_config for this sector has not been provided. However, the company's operating cash flow is a key indicator of its ability to generate cash from core operations, which is essential for sustaining growth and meeting financial obligations. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segment or geographic diversification may expose the company to higher operational and market risks, particularly in the pharmaceuticals industry where regulatory and market conditions can vary significantly by region. Looking ahead, the company's growth trajectory is not yet quantified in the outlook data. However, the significant capital expenditures suggest a focus on long-term investment, which could support future revenue growth. The company's revenue for the latest period was 3,611,781,000 CNY, but without a clear direction or numeric delta for the current or next fiscal year, it is difficult to assess the pace of growth. The company's risk profile includes a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential challenges in maintaining liquidity. However, the low dilution risk suggests that the company is not currently under pressure to issue additional shares, which could dilute existing shareholders' equity. Recent events and filings have not been disclosed in the available data, so there is no information on recent strategic moves, regulatory changes, or other developments that could impact the company's performance. Investors should monitor the company's future filings and disclosures for any material changes in its business or financial position.

30-day price · 002562(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyBrother Enterprises Holding Co Ltd
Ticker002562.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Brother Enterprises Holding Co Ltd operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Classification. The company is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Brother Enterprises Holding Co Ltd has a debt-to-equity ratio of 0.43, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a negative net cash position after subtracting total debt, suggesting potential short-term liquidity constraints. Operating cash flow for the latest period was 7,098,720 CNY, which is significantly lower in magnitude compared to capital expenditures of -73,804,460 CNY, indicating a net cash outflow from operations. In terms of profitability, the company's financial performance is not yet benchmarked against industry-specific metrics, as the industry_config for this sector has not been provided. However, the company's operating cash flow is a key indicator of its ability to generate cash from core operations, which is essential for sustaining growth and meeting financial obligations. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segment or geographic diversification may expose the company to higher operational and market risks, particularly in the pharmaceuticals industry where regulatory and market conditions can vary significantly by region. Looking ahead, the company's growth trajectory is not yet quantified in the outlook data. However, the significant capital expenditures suggest a focus on long-term investment, which could support future revenue growth. The company's revenue for the latest period was 3,611,781,000 CNY, but without a clear direction or numeric delta for the current or next fiscal year, it is difficult to assess the pace of growth. The company's risk profile includes a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential challenges in maintaining liquidity. However, the low dilution risk suggests that the company is not currently under pressure to issue additional shares, which could dilute existing shareholders' equity. Recent events and filings have not been disclosed in the available data, so there is no information on recent strategic moves, regulatory changes, or other developments that could impact the company's performance. Investors should monitor the company's future filings and disclosures for any material changes in its business or financial position.
Key takeaways
  • The company maintains a conservative capital structure with a debt-to-equity ratio of 0.43.
  • Operating cash flow is significantly lower than capital expenditures, indicating a net cash outflow from operations.
  • The company's liquidity position is assessed as medium, with a negative net cash position after subtracting total debt.
  • The company's growth trajectory is not yet quantified, but significant capital expenditures suggest a focus on long-term investment.
  • The company's risk profile includes a medium liquidity risk and a low dilution risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$3.61B
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow$7.1M
CapEx-$73.8M
Free cash flow
Total assets
Total liabilities$2.51B
Total equity$3.69B
Cash & equivalents
Long-term debt$1.59B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash-$1.59B
Current ratio
Debt/Equity0.4
ROA
ROE
Cash conversion
CapEx/Revenue-2.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric002562Activity
Op margin18.2% medp25 18.2% · p75 24.6%
Net margin14.7% medp25 11.7% · p75 28.1%
Gross margin19.7% medp25 19.7% · p75 39.8%
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-2.0%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity43.0%71.3% medp25 19.0% · p75 91.7%below median
Source: analysis-pipeline (hybrid)Generated: 2026-05-20 02:07 UTCJob: 1db74299